2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P1144
    Oxyntomodulin (bovine, porcine) 62340-29-8 99.77%
    Oxyntomodulin (bovine, porcine), a 37-amino acid peptide hormone, is a glucagon-like peptide 1 (GLP-1) receptor agonist.
    Oxyntomodulin (bovine, porcine)
  • HY-P1775
    Carbonic anhydrase, Bovine erythrocytes 9001-03-0
    Carbonic anhydrase, Bovine erythrocytes (EC 4.2.1.1) is ubiquitous zinc-containing metalloenzyme present in prokaryotes and eukaryotes. Carbonic anhydrase can catalyze reversible conversion of carbon dioxide to bicarbonate and protons. Carbonic anhydrase can be used for the research of cancer, glaucoma, obesity and epilepsy.
    Carbonic anhydrase, Bovine erythrocytes
  • HY-P1777
    IGF-I (24-41) 135861-49-3 99.11%
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development.
    IGF-I (24-41)
  • HY-P4116
    pH-Low Insertion Peptide 2293160-09-3 99.38%
    pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors.
    pH-Low Insertion Peptide
  • HY-P5832
    BMP2-derived peptide 836606-84-9 98.04%
    BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research.
    BMP2-derived peptide
  • HY-103355
    YM022 145084-28-2 ≥99.0%
    YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo.
    YM022
  • HY-107480
    YK11 1370003-76-1 98.18%
    YK11 is a partial agonist of androgen receptor, with osteogenic activity.
    YK11
  • HY-108767
    Insulin aspart 116094-23-6
    Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research.
    Insulin aspart
  • HY-11030A
    SNT-207858 free base 1104662-66-9 99.66%
    SNT207858 free base is a selective, blood brain barrier penetrating, potent and orally active melanocortin-4 (MC-4) receptor antagonist. SNT207858 free base has an IC50 of 22 nM (binding) and 11 nM (function) on the MC-4 receptor.
    SNT-207858 free base
  • HY-112322
    Carbacyclin 69552-46-1 99.37%
    Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
    Carbacyclin
  • HY-113220
    Monoisobutyl phthalic acid 30833-53-5
    Monoisobutyl phthalic acid is a phthalate metabolite that is in human semen and in meconium.
    Monoisobutyl phthalic acid
  • HY-113955
    CP-346086 186390-48-7 99.18%
    CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo.
    CP-346086
  • HY-116263
    CATPB 1322598-09-3 ≥99.0%
    CATPB is a potent, selective free fatty acid receptor 2 (FFA2R/GPR43) antagonist.
    CATPB
  • HY-119737
    Chlorsulfuron 64902-72-3 99.95%
    Chlorsulfuron blocks the biosynthesis of the amino acids valine and isoleucine in plants. Chlorsulfuron completely alleviates herbicide-induced growth inhibition. The site of action of Chlorsulfuron is the enzyme acetolactate synthase.
    Chlorsulfuron
  • HY-123037
    Triadimefon 43121-43-3 98.12%
    Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory.
    Triadimefon
  • HY-126146
    PKC-iota inhibitor 1 2328094-11-5 99.60%
    PKC-iota inhibitor 1 is a protein kinase C-iota (PKC-ι) inhibitor with an IC50 value of 0.34 μM. PKC-iota inhibitor 1 can be used for the study of cancer.
    PKC-iota inhibitor 1
  • HY-127034
    Antipain dihydrochloride 37682-72-7
    Antipain dihydrochloride is a protease inhibitor isolated from Actinomycetes. Antipain dihydrochloride inhibits N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced transformation and increases chromosomal aberrations. Antipain dihydrochloride restricts uterine DNA synthesis and function in mice.
    Antipain dihydrochloride
  • HY-128057
    NCRW0005-F05 342779-66-2 99.94%
    NCRW0005-F05 is a potent GPR139 antagonist with an IC50 value of 0.21 μM. NCRW0005-F05 can be used to research diabetes, obesity and Parkinson's disease.
    NCRW0005-F05
  • HY-128442
    Phenyl sulfate 937-34-8 99.47%
    Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker in diabetic kidney disease.
    Phenyl sulfate
  • HY-128749
    D-Glucaric acid potassium 576-42-1 98.0%
    D-Glucaric acid potassium (Potassium D-glucarate) is an orally active end product of the D-glucuronic acid pathway in mammals. D-Glucaric acid potassium is present in a variety of fruits and vegetables. D-Glucaric acid potassium has cholesterol-lowering and anti-tumor activities. D-Glucaric acid potassium can inhibit tumor cell proliferation and inflammation, and induce apoptosis.
    D-Glucaric acid potassium
Cat. No. Product Name / Synonyms Application Reactivity